SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 42   

Articles published

SCLN 6.95 +0.09 (1.30%)
price chart
SciClone Pharmaceuticals's �Buy� Rating Reiterated at Aegis (SCLN)
SciClone Pharmaceuticals (NASDAQ:SCLN) last released its earnings data on Monday, August 11th. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.10.
SciClone Pharmaceuticals (SCLN) Gains; DC Bead Approved by China FDA
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), and its partner BTG plc today announced that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularized tumors.
Sector Update: Health-Care Shares Aim Lower in Pre-Market Trade  NASDAQ
Chinese FDA approves DC Bead for liver cancer treatment  pharmabiz.com
Related articles »  
SciClone Pharmaceuticals Inc. (SCLN) Issues FY14 Earnings Guidance
SciClone Pharmaceuticals logo SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) issued an update on its FY14 earnings guidance on Monday morning.
SciClone Pharmaceuticals (SCLN) Posts Quarterly Earnings, Beats Estimates By ...  WKRB News
Related articles »  
SciClone Pharma, BTG Say China's FDA Approves DC Bead
SciClone Pharmaceuticals, Inc. (SCLN: Quote), and its partner BTG plc (BTG.L), Thursday said the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularized tumors.
Aegis Reiterates "Buy" Rating for SciClone Pharmaceuticals (SCLN)
SciClone Pharmaceuticals Inc. logo SciClone Pharmaceuticals (NASDAQ:SCLN)'s stock had its �buy� rating reaffirmed by investment analysts at Aegis in a note issued to investors on Friday.
SciClone Pharmaceuticals's "Buy" Rating Reiterated at Aegis (SCLN)  Mideast Time
Related articles »  
Aegis Reaffirms Buy Rating for SciClone Pharmaceuticals (SCLN)
SciClone Pharmaceuticals has a one year low of $4.24 and a one year high of $7.02. The stock has a 50-day moving average of $5.51 and a 200-day moving average of $5.01.
SciClone Pharmaceuticals Director Nancy T. Chang Acquires 25040 Shares ...
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Monday, August 11th. The company reported $0.20 earnings per share for the quarter, beating the analysts' consensus estimate of $0.10 by $0.10.
Insider Buying: SciClone Pharmaceuticals Director Buys 25040 Shares of Stock ...  sleekmoney
Insider Buying: SciClone Pharmaceuticals Director Purchases 25040 Shares of ...  Ticker Report
Related articles »  
SciClone Pharmaceuticals (SCLN) to Release Earnings on Monday
The company had revenue of $26.60 million for the quarter, compared to the consensus estimate of $32.20 million. During the same quarter last year, the company posted $0.08 earnings per share. SciClone Pharmaceuticals's revenue was down 10.7% ...
Stocks to Keep Your Eyes on: SciClone Pharmaceuticals, Inc. (SCLN), OraSure ...
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) augmented +8.83% to close at $6.90 in the last trading session and its total traded volume was 852,981 shares versus average volume of 274,367.
Morning Buzz: SciClone Pharmaceuticals (NASDAQ:SCLN), Progressive Corp ...
On 31 JULY SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) announced that it plans to report financial results for the second quarter 2014 on Monday, August 11, 2014.
Related articles »